RetroSense Therapeutics was purchased by Allergan PLC in … with an initial payout of $60M. Expected payments thereafter exceed $550M. BlueWater Angels provided seed round funding for RetroSense in March 2014, follow-on funding in RetroSense’s B Round in 2015, and bridge funding in 2016 for a total of $2.2M invested. Syndicated investors brought this total to $15M.
Gemphire Therapeutics launch an Initial Public Offering (IPO) in August 2016. Gemphire’s IPO price was $10.00. BlueWater Angels provided seed funding in March 2015 and raised additional Venture Capital funding of $2,800,000 in July 2015. Gemphire Therapeutic’s current stock information can be found on NASDAQ.
ProNai Therapeutics, now known as Sierra Oncology, launched an Initial Public Offreing (IPO) in July 2015. ProNai’s IPO price was $17.00. BlueWater Angels provided Series C funding in August 2012, and a further 2 rounds in 2013. Sierra Oncology’s current stock information can be found on Yahoo! Finance.